Format

Send to

Choose Destination
Alzheimers Dement. 2015 Jul;11(7):850-9. doi: 10.1016/j.jalz.2015.05.008.

The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update.

Author information

1
Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA. Electronic address: jhendrix@alz.org.
2
Independent Science Writer, Evanston, IL, USA.
3
Center for Imaging of Neurodegenerative Diseases (CIND), Northern California Institute of Research, San Francisco VA Medical Center, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, CA, USA.
4
Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland.
5
Department of Neuropathology, Graduate School of Medicine, the University Hospital of Tokyo, Japan.
6
Department of Molecular Imaging, Austin Health, Melbourne, Australia.
7
Department of Psychiatry, Asian Medical Center, Seoul, Republic of Korea.
8
Aging and Memory Center, Instituto de Investigaciones Neurologicas Raul Carrea (FLENI), Buenos Aires, Argentina.
9
Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA.

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI), launched in 2004, has worked to accelerate drug development by validating imaging and blood/cerebrospinal fluid biomarkers for Alzheimer's disease clinical treatment trials. ADNI is a naturalistic (nontreatment) multisite longitudinal study. A true public-private partnership, the initiative has set a new standard for data sharing without embargo and for the use of biomarkers in dementia research. The ADNI effort in North America is not the only such effort in the world. The Alzheimer's Association recognized these global efforts and formed Worldwide ADNI (WW-ADNI). By creating a platform for international collaboration and cooperation, WW-ADNI's goals are to harmonize projects and results across geographical regions and to facilitate data management and availability to investigators around the world. WW-ADNI projects include those based in North America, Europe, Japan, Australia, Korea, and Argentina.

KEYWORDS:

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Neuroimaging

PMID:
26194318
DOI:
10.1016/j.jalz.2015.05.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center